Immunotherapy involving anti-PD-1/PD-L1 has resulted in revolutionary therapeutic benefits for various cancer types, and MSI-H status has proven to be an effective predictor of immunotherapeutic efficacy [36]. This evidence concerns the gene PDCD1 and cancer.